CA2956646A1 - Procedes et compositions pour diagnostiquer, pronostiquer et confirmer une pre-eclampsie. - Google Patents
Procedes et compositions pour diagnostiquer, pronostiquer et confirmer une pre-eclampsie. Download PDFInfo
- Publication number
- CA2956646A1 CA2956646A1 CA2956646A CA2956646A CA2956646A1 CA 2956646 A1 CA2956646 A1 CA 2956646A1 CA 2956646 A CA2956646 A CA 2956646A CA 2956646 A CA2956646 A CA 2956646A CA 2956646 A1 CA2956646 A1 CA 2956646A1
- Authority
- CA
- Canada
- Prior art keywords
- biomarkers
- preeclampsia
- levels
- p1gf
- sflt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 949
- 238000000034 method Methods 0.000 title claims abstract description 546
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 89
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 81
- 238000012544 monitoring process Methods 0.000 claims abstract description 47
- 239000000090 biomarker Substances 0.000 claims description 655
- 102100037362 Fibronectin Human genes 0.000 claims description 372
- 108010067306 Fibronectins Proteins 0.000 claims description 372
- 102100035194 Placenta growth factor Human genes 0.000 claims description 301
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 299
- 239000000523 sample Substances 0.000 claims description 287
- 108030001694 Pappalysin-1 Proteins 0.000 claims description 146
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 238000012360 testing method Methods 0.000 claims description 115
- 238000003556 assay Methods 0.000 claims description 114
- 102000004169 proteins and genes Human genes 0.000 claims description 96
- 108091007507 ADAM12 Proteins 0.000 claims description 83
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 claims description 83
- -1 sFLT1 Proteins 0.000 claims description 58
- 102100033226 Pikachurin Human genes 0.000 claims description 56
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 54
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 54
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 54
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 54
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 54
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 54
- 108090000712 Cathepsin B Proteins 0.000 claims description 54
- 102000004225 Cathepsin B Human genes 0.000 claims description 54
- 102000003902 Cathepsin C Human genes 0.000 claims description 54
- 108090000267 Cathepsin C Proteins 0.000 claims description 54
- 102000008857 Ferritin Human genes 0.000 claims description 54
- 108050000784 Ferritin Proteins 0.000 claims description 54
- 238000008416 Ferritin Methods 0.000 claims description 54
- 102000014702 Haptoglobin Human genes 0.000 claims description 54
- 108050005077 Haptoglobin Proteins 0.000 claims description 54
- 102000001554 Hemoglobins Human genes 0.000 claims description 54
- 108010054147 Hemoglobins Proteins 0.000 claims description 54
- 102100038246 Retinol-binding protein 4 Human genes 0.000 claims description 54
- 101710137011 Retinol-binding protein 4 Proteins 0.000 claims description 54
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 52
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 52
- 208000024891 symptom Diseases 0.000 claims description 48
- 238000012790 confirmation Methods 0.000 claims description 43
- 230000006870 function Effects 0.000 claims description 43
- 230000002159 abnormal effect Effects 0.000 claims description 40
- 238000004458 analytical method Methods 0.000 claims description 39
- 238000012549 training Methods 0.000 claims description 39
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 38
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 38
- 238000003745 diagnosis Methods 0.000 claims description 36
- 230000036772 blood pressure Effects 0.000 claims description 32
- 206010020772 Hypertension Diseases 0.000 claims description 31
- 238000004393 prognosis Methods 0.000 claims description 31
- 229940012952 fibrinogen Drugs 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 30
- 238000009595 pap smear Methods 0.000 claims description 30
- 238000002965 ELISA Methods 0.000 claims description 29
- 101710178799 Pikachurin Proteins 0.000 claims description 29
- 150000003278 haem Chemical class 0.000 claims description 29
- 108010049003 Fibrinogen Proteins 0.000 claims description 27
- 102000008946 Fibrinogen Human genes 0.000 claims description 27
- 101000851265 Homo sapiens Pikachurin Proteins 0.000 claims description 27
- 230000001684 chronic effect Effects 0.000 claims description 27
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 24
- 208000021017 Weight Gain Diseases 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 22
- 208000017169 kidney disease Diseases 0.000 claims description 22
- 230000004584 weight gain Effects 0.000 claims description 22
- 235000019786 weight gain Nutrition 0.000 claims description 22
- 239000012472 biological sample Substances 0.000 claims description 21
- 210000002700 urine Anatomy 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 238000003018 immunoassay Methods 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 18
- 206010019233 Headaches Diseases 0.000 claims description 17
- 206010020608 Hypercoagulation Diseases 0.000 claims description 17
- 206010030113 Oedema Diseases 0.000 claims description 17
- 231100000869 headache Toxicity 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 201000005665 thrombophilia Diseases 0.000 claims description 17
- 208000008589 Obesity Diseases 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 235000020824 obesity Nutrition 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 16
- 238000012512 characterization method Methods 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 13
- 229940109239 creatinine Drugs 0.000 claims description 12
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 11
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 11
- 101000610209 Homo sapiens Pappalysin-2 Proteins 0.000 claims description 11
- 102100040154 Pappalysin-2 Human genes 0.000 claims description 11
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 11
- 230000009466 transformation Effects 0.000 claims description 11
- 208000024320 Abnormal platelet count Diseases 0.000 claims description 10
- 206010000188 Abnormal weight gain Diseases 0.000 claims description 10
- 238000010324 immunological assay Methods 0.000 claims description 9
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 230000002860 competitive effect Effects 0.000 claims description 7
- 230000000951 immunodiffusion Effects 0.000 claims description 7
- 230000036765 blood level Effects 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000012935 Averaging Methods 0.000 claims description 5
- 206010033307 Overweight Diseases 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 238000004848 nephelometry Methods 0.000 claims description 5
- 238000003118 sandwich ELISA Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 235000020825 overweight Nutrition 0.000 claims description 4
- 206010011703 Cyanosis Diseases 0.000 claims description 3
- 206010030302 Oliguria Diseases 0.000 claims description 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
- 238000012896 Statistical algorithm Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 208000005333 pulmonary edema Diseases 0.000 claims description 3
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 claims 31
- 102100034629 Hemopexin Human genes 0.000 claims 19
- 101001067323 Homo sapiens Hemopexin Proteins 0.000 claims 19
- 102100040156 Pappalysin-1 Human genes 0.000 description 218
- 101000610206 Homo sapiens Pappalysin-1 Proteins 0.000 description 103
- 102000013271 Hemopexin Human genes 0.000 description 101
- 108010026027 Hemopexin Proteins 0.000 description 101
- 235000018102 proteins Nutrition 0.000 description 81
- 239000002609 medium Substances 0.000 description 74
- 239000003550 marker Substances 0.000 description 70
- 230000035935 pregnancy Effects 0.000 description 51
- 238000011282 treatment Methods 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 35
- 238000008157 ELISA kit Methods 0.000 description 33
- 230000000670 limiting effect Effects 0.000 description 29
- 230000000875 corresponding effect Effects 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 238000001514 detection method Methods 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 18
- 238000003908 quality control method Methods 0.000 description 17
- 206010016807 Fluid retention Diseases 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000013615 primer Substances 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 12
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 12
- 229960001138 acetylsalicylic acid Drugs 0.000 description 12
- 229960000074 biopharmaceutical Drugs 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000004104 gestational diabetes Diseases 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000002483 medication Methods 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 239000013062 quality control Sample Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012706 support-vector machine Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 208000000995 spontaneous abortion Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241001316595 Acris Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 108010046334 Urease Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000011551 log transformation method Methods 0.000 description 6
- 230000008774 maternal effect Effects 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 238000004885 tandem mass spectrometry Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 206010061452 Complication of pregnancy Diseases 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 206010070538 Gestational hypertension Diseases 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 229920002113 octoxynol Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000036266 weeks of gestation Effects 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 238000001854 atmospheric pressure photoionisation mass spectrometry Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007635 classification algorithm Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001429 visible spectrum Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 102400000525 Fibrinopeptide A Human genes 0.000 description 2
- 101800000974 Fibrinopeptide A Proteins 0.000 description 2
- 241000287826 Gallus Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000693844 Homo sapiens Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
- 102100025515 Insulin-like growth factor-binding protein complex acid labile subunit Human genes 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101150062285 PGF gene Proteins 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108091028733 RNTP Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000003094 enzyme-multiplied immunoassay technique Methods 0.000 description 2
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 2
- 108010052295 fibrin fragment D Proteins 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- 102000029791 ADAM Human genes 0.000 description 1
- 108091022885 ADAM Proteins 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 101710202200 Endolysin A Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 102100024521 Ficolin-2 Human genes 0.000 description 1
- 101710155249 Ficolin-2 Proteins 0.000 description 1
- 102100024520 Ficolin-3 Human genes 0.000 description 1
- 101710155250 Ficolin-3 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000091 Maternal Death Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-MPSLMFKFSA-N aprotinin Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H]3CCCN3C(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N3CCC[C@@H]3C(=O)N3CCC[C@H]3C(=O)N[C@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](NC1=O)[C@H](C)CC)[C@@H](C)O)C(C)C ZPNFWUPYTFPOJU-MPSLMFKFSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000005109 two-dimensional liquid chromatography tandem mass spectrometry Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031132P | 2014-07-30 | 2014-07-30 | |
| US62/031,132 | 2014-07-30 | ||
| US201462031834P | 2014-07-31 | 2014-07-31 | |
| US62/031,834 | 2014-07-31 | ||
| US201562115077P | 2015-02-11 | 2015-02-11 | |
| US62/115,077 | 2015-02-11 | ||
| PCT/US2015/042976 WO2016019176A1 (fr) | 2014-07-30 | 2015-07-30 | Procédés et compositions pour diagnostiquer, pronostiquer et confirmer une pré-éclampsie. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2956646A1 true CA2956646A1 (fr) | 2016-02-04 |
Family
ID=55218328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2956646A Abandoned CA2956646A1 (fr) | 2014-07-30 | 2015-07-30 | Procedes et compositions pour diagnostiquer, pronostiquer et confirmer une pre-eclampsie. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3175239A1 (fr) |
| CN (1) | CN107155350A (fr) |
| CA (1) | CA2956646A1 (fr) |
| MA (1) | MA40325A (fr) |
| WO (1) | WO2016019176A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017148854A1 (fr) * | 2016-02-29 | 2017-09-08 | Roche Diagnostics Gmbh | Utilisation d'igfbp-7 comme marqueur de pré-éclampsie |
| FR3057070B1 (fr) * | 2016-10-04 | 2018-11-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Diagnostique et pronostique precoce de la preeclampsie |
| CN107312846A (zh) * | 2017-07-12 | 2017-11-03 | 北京赛尔维康生物医学科技有限公司 | Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用 |
| US20200264188A1 (en) | 2017-09-13 | 2020-08-20 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| JP7319553B2 (ja) * | 2017-10-23 | 2023-08-02 | シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー | 在胎週数および早産を予測する胎児発達のための非侵襲的分子時計 |
| WO2019155075A1 (fr) * | 2018-02-09 | 2019-08-15 | Metabolomic Diagnostics Limited | Méthodes pour prévoir la naissance avant terme en raison d'une prééclampsie au moyen de biomarqueurs métaboliques et protéiques |
| CN108717123A (zh) * | 2018-04-25 | 2018-10-30 | 卢英 | 一种联合检测sFlt-1/PLGF和HLA-G检测先兆子痫的方法 |
| CN112673259B (zh) * | 2018-07-20 | 2024-11-22 | 豪夫迈·罗氏有限公司 | 基于igfbp-7的先兆子痫预测 |
| KR20200049365A (ko) * | 2018-10-31 | 2020-05-08 | 서울대학교산학협력단 | 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커 |
| CN109554479A (zh) * | 2019-01-21 | 2019-04-02 | 中南大学 | Pigc基因在制备肝癌辅助诊断及预后判断制剂上的应用 |
| CN109919054B (zh) * | 2019-02-25 | 2023-04-07 | 电子科技大学 | 一种基于机器视觉的试剂卡自动分类的检测方法 |
| CN110596386B (zh) * | 2019-09-20 | 2020-06-02 | 四川大学华西医院 | Egflam自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN112710836A (zh) * | 2019-10-25 | 2021-04-27 | 成都敬守务成医疗科技有限责任公司 | 人类白细胞抗原g标志物的用途及试剂盒 |
| EP4070113A4 (fr) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié |
| CN112180098B (zh) * | 2019-12-06 | 2023-02-17 | 中山大学 | 胎盘相关疾病标志物的筛选方法及标志物 |
| CN111257445B (zh) * | 2020-01-22 | 2022-09-09 | 上海交通大学医学院附属仁济医院 | 用于sle孕妇病情监测及其胎儿结局预测的产品及方法 |
| CN113495147A (zh) * | 2020-03-19 | 2021-10-12 | 首都医科大学附属北京世纪坛医院 | 尿液α2-巨球蛋白及其多肽片段在妊娠糖尿病中的应用 |
| CN112305220B (zh) * | 2020-06-03 | 2021-07-23 | 四川大学华西第二医院 | 组织蛋白酶z在子痫前期的早期预警、诊断中的应用和产品 |
| KR102233909B1 (ko) * | 2020-07-13 | 2021-03-30 | 서울대학교산학협력단 | 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커 |
| CN111951969A (zh) * | 2020-08-05 | 2020-11-17 | 中翰盛泰生物技术股份有限公司 | Hbp在高危妊娠预测中的应用 |
| GB202012830D0 (en) * | 2020-08-17 | 2020-09-30 | Univ Tartu | Method of prognosing preeclampsia |
| CN112175963A (zh) * | 2020-09-30 | 2021-01-05 | 安徽省天长市周氏羊业有限公司 | 一种spp1基因及评估绵羊单卵泡中高尔基体发育质量的方法 |
| CN112535886B (zh) * | 2020-11-12 | 2022-07-12 | 杭州苏铂科技有限公司 | 去除金纳米棒溶液中的ctab的方法 |
| CN112946299B (zh) * | 2021-01-29 | 2022-11-29 | 暨南大学 | 定量ftl的产品在制备子痫前期诊断工具中的应用 |
| CN112946283B (zh) * | 2021-01-29 | 2022-11-29 | 暨南大学 | 定量a2m的产品在制备子痫前期诊断工具中的应用 |
| CN113092777B (zh) * | 2021-03-26 | 2023-11-14 | 泰达国际心血管病医院 | 孕早期进行重症子痫前期患者筛查的方法 |
| EP4430406A4 (fr) * | 2021-11-11 | 2025-10-15 | Nx Prenatal Inc | Procédés de préparation et d'analyse d'échantillons pour biomarqueurs associés au placenta accreta |
| CN115308423B (zh) * | 2022-10-10 | 2023-02-10 | 天津云检医疗器械有限公司 | 用于先兆子痫风险预测、评估或诊断的生物标志物、试剂盒及方法 |
| CN117647653B (zh) * | 2023-12-22 | 2024-05-07 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一种与子痫前期相关的生物标志物及其应用 |
| CN118593717A (zh) * | 2024-05-31 | 2024-09-06 | 厦门特宝生物工程股份有限公司 | 一种用于治疗和/或预防子痫前期发生的药物组合物及其应用 |
| CN119230113A (zh) * | 2024-09-30 | 2024-12-31 | 常州市妇幼保健院 | 胎盘植入性疾病早期识别及严重程度预测的分类器及其训练系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1839056B1 (fr) * | 2004-12-21 | 2011-08-03 | Yale University | Diagnostic de la preeclampsie |
| WO2009097584A1 (fr) * | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Biomarqueurs de sérum maternel pour la détection de pré-éclampsie |
| CN104487593A (zh) * | 2012-05-08 | 2015-04-01 | 斯坦福大学托管董事会 | 用于提供先兆子痫评估的方法和组合物 |
| US20140141456A1 (en) * | 2012-08-30 | 2014-05-22 | Ansh Labs, LLC | Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia |
-
2015
- 2015-07-30 CN CN201580052632.5A patent/CN107155350A/zh active Pending
- 2015-07-30 EP EP15826348.3A patent/EP3175239A1/fr not_active Withdrawn
- 2015-07-30 MA MA040325A patent/MA40325A/fr unknown
- 2015-07-30 WO PCT/US2015/042976 patent/WO2016019176A1/fr not_active Ceased
- 2015-07-30 CA CA2956646A patent/CA2956646A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016019176A1 (fr) | 2016-02-04 |
| EP3175239A1 (fr) | 2017-06-07 |
| CN107155350A (zh) | 2017-09-12 |
| MA40325A (fr) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2956646A1 (fr) | Procedes et compositions pour diagnostiquer, pronostiquer et confirmer une pre-eclampsie. | |
| US20240318250A1 (en) | Biomarker pairs for predicting preterm birth | |
| JP2023110034A (ja) | 臨床的介入のための妊娠の進展および早期流産の評価方法およびその応用 | |
| US20150099655A1 (en) | Methods and Compositions for Providing a Preeclampsia Assessment | |
| JP6691617B2 (ja) | 子癇前症の評価を提供するための方法及び組成物 | |
| US20100029006A1 (en) | Multiplexed diagnostic test for preterm labor | |
| WO2017181367A1 (fr) | Procédés et compositions pour pronostiquer une naissance prématurée | |
| US9983215B2 (en) | Methods and compositions for diagnosis of ectopic pregnancy | |
| CN109891239B (zh) | 用于提供子痫前期评估和预测早产的方法和试剂盒 | |
| CN110191963A (zh) | 用于预测由于早产胎膜早破相对于特发性自然分娩所造成的早产的生物标志物 | |
| WO2008145701A1 (fr) | Procédé de prédiction de l'évolution d'un patient malade de manière critique | |
| KR102770814B1 (ko) | 자궁경부암의 예후 및 동시항암화학방사선 요법에 대한 치료 반응 예측에 대한 바이오마커 및 이를 이용한 정보 제공방법 | |
| WO2024037387A1 (fr) | Biomarqueurs sanguins et procédés de diagnostic de la maladie de kawasaki aiguë | |
| HK40107594A (en) | Biomarker pairs for predicting preterm birth | |
| WO2022186821A1 (fr) | Méthodes et compositions pour fournir une évaluation de prééclampsie à l'aide de leptine et de céramide | |
| WO2025238203A1 (fr) | Marqueurs et leur utilisation dans le cadre d'un traumatisme crânio-cérébral | |
| WO2021024009A1 (fr) | Procédés et compositions pour fournir une évaluation du cancer du côlon à l'aide de biomarqueurs protéiques | |
| BR122024018561A2 (pt) | Composição, painel, método para determinar a probabilidade de parto prematuro em uma fêmea grávida e método de detecção de ibp4 e shbg em uma fêmea grávida | |
| HK1254669B (en) | Biomarker pairs for predicting preterm birth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190730 |